Microscopic view of human stem cells in culture
FOUNDATIONAL

What Are Stem Cells? Your Body's Natural Healing System

Discover how stem cells—your body's master repair system—work to heal damaged tissue. Learn about MSCs, exosomes, and why umbilical cord stem cells offer unique advantages for regenerative therapy.

Medical Content Team Content Team
February 8, 2026 · 25 min read

Key Takeaways

  • Stem cells are your body's "master cells": they can become many different cell types and help repair damaged tissue
  • You have stem cells right now, working to maintain and heal your body every day
  • Three main types matter for treatment: embryonic, adult (including mesenchymal), and induced pluripotent
  • Mesenchymal stem cells (MSCs) are the most commonly used in regenerative medicine: for joint pain, lung conditions, autoimmune disorders, and chronic diseases
  • Umbilical cord MSCs offer distinct advantages: young, potent cells with anti-aging properties: available immediately without invasive harvesting
  • Exosomes: tiny messenger particles released by stem cells: are emerging as a powerful therapeutic tool in their own right
  • Stem cell therapy harnesses your body's natural healing: it's not about adding something foreign, but amplifying what your body already does
  • The healthier you are, the better stem cells tend to work: clinical evidence now supports MSC therapy for optimization and longevity, not just disease treatment

The Problem: Why Understanding Stem Cells Matters

If you're reading this, chances are you or someone you love is dealing with chronic pain, a degenerative condition, or an injury that won't heal. Maybe you've been told:

  • "You'll need a knee replacement eventually"
  • "There's nothing more we can do—just manage the pain"
  • "Your cartilage is gone, bone-on-bone"
  • "You'll be on oxygen for the rest of your life"

These diagnoses can feel like a life sentence. But here's what most people don't know: your body has a built-in repair system. It's been working since before you were born. The question isn't whether stem cells work—it's whether we can help them work better for you.

Understanding stem cells is the first step toward understanding your options.

What Are Stem Cells? (The Simple Explanation)

Think of stem cells as blank building blocks that can become almost any type of cell your body needs.

Most cells in your body are specialists. A skin cell is always a skin cell. A heart muscle cell is always a heart muscle cell. They can't change jobs.

Stem cells are different. They're unspecialized—meaning they haven't decided what to become yet. This gives them two remarkable abilities:

  1. Self-renewal: They can divide and make copies of themselves
  2. Differentiation: They can transform into specialized cells (muscle, bone, cartilage, nerve, etc.)

A Real-World Analogy: Imagine a construction company. Most workers are specialists—electricians, plumbers, carpenters. They're excellent at their job, but an electrician can't suddenly become a plumber. Stem cells are like apprentices who haven't specialized yet. They can be trained to become whatever the job site needs most.

This is why stem cells are so valuable for healing. When you have damaged cartilage in your knee or scarred tissue in your lungs, your body needs new healthy cells. Stem cells can potentially become those cells and help repair the damage.

Where Do Stem Cells Come From?

You have stem cells in your body right now. They're working constantly to replace worn-out cells and repair minor damage. But their numbers and potency decrease as we age—which is partly why healing takes longer when you're older.

The Main Sources

For regenerative treatments targeting joint pain, orthopedic injuries, respiratory conditions, or degenerative diseases, mesenchymal stem cells (MSCs) from bone marrow, adipose tissue, or umbilical cord are most commonly used. [1]

Types of Stem Cells: What You Need to Know

Not all stem cells are equal. They differ in their potency—how many different cell types they can become.

The Potency Spectrum

The Three Types That Matter Most

1. Embryonic Stem Cells (ESCs)

What they are: Derived from early-stage embryos (3–5 days after fertilization). Pluripotent—can become almost any cell type.

For patients: These are primarily used in research. Ethical considerations and regulatory restrictions limit their clinical use. You're unlikely to encounter these in treatment settings.

2. Adult Stem Cells (Including MSCs)

What they are: Found throughout your body in bone marrow, fat, blood, and other tissues. Multipotent—can become several related cell types.

For patients: This is what most regenerative treatments use. Mesenchymal stem cells (MSCs) are the "workhorses" of regenerative medicine. [2]They can become:

  • Bone cells (osteocytes)
  • Cartilage cells (chondrocytes)
  • Fat cells (adipocytes)
  • Muscle cells
  • And potentially others

Key advantage: Can be harvested from your own body (autologous) or from ethically-sourced donors (allogeneic), with minimal rejection risk.

3. Induced Pluripotent Stem Cells (iPSCs)

What they are: Adult cells that have been reprogrammed back to a pluripotent state using specific genes. Created in labs. [3]

For patients: Still primarily in research. Revolutionary for disease modeling and drug testing. Clinical applications are emerging but not yet widespread.

How Do Stem Cells Actually Heal?

This is where it gets interesting. For years, scientists believed stem cells healed simply by becoming new tissue. You inject stem cells, they turn into cartilage, problem solved.

The reality is more nuanced—and potentially more powerful.

The Four Mechanisms of Healing

1. Direct Differentiation (Becoming New Cells)

Yes, stem cells can become new tissue. MSCs injected into a damaged knee can differentiate into cartilage cells. [4]But this accounts for only a portion of the healing effect.

2. Paracrine Signaling (The Orchestra Conductor)

Stem cells release signaling molecules—growth factors, cytokines, and chemokines—that: [5]

  • Recruit your body's own repair cells to the injury site
  • Reduce inflammation
  • Promote blood vessel formation (angiogenesis)
  • Stimulate local stem cells to activate

Think of it this way: stem cells don't just become new workers—they also call in reinforcements and coordinate the repair effort.

3. Exosome Release (Cellular Messaging)

Stem cells release tiny packages called exosomes (30–150 nanometers in size) containing proteins, lipids, and genetic material. [6]These exosomes can:

  • Transfer healing signals to nearby cells
  • Modify the behavior of damaged tissue
  • Reduce scarring and fibrosis
  • Cross barriers that cells cannot (including the blood-brain barrier)

Exosomes are becoming a major focus in regenerative medicine. Research shows that MSC-derived exosomes can recapitulate many therapeutic benefits of stem cells while avoiding risks associated with cell transplantation. [7]This is why many advanced treatment protocols now combine MSC therapy with exosome therapy for enhanced results.

4. Immunomodulation (Calming the Storm)

MSCs actively modulate immune responses, which is crucial for conditions involving chronic inflammation: [8]

  • Suppress overactive T-cell responses
  • Reduce pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
  • Promote regulatory T-cells that maintain immune balance
  • Shift the immune system from "attack mode" to "repair mode"

What this means for you: Stem cell therapy isn't just about adding new cells. It's about activating and optimizing your body's entire healing response while calming inflammation that prevents healing.

The Science: How We Know This Works

Understanding the science helps you make informed decisions. Here's what the research shows.

Clinical Evidence for MSC Therapy

Mesenchymal stem cells have been studied extensively across multiple conditions:

Knee Osteoarthritis: A comprehensive review by Copp, Robb, and Viswanathan (2023) evaluated 26 clinical trials (15 randomized controlled trials and 11 non-randomized studies) involving 610 patients. The analysis found that MSC treatment resulted in improved function in 12 of 15 RCTs compared to baseline, and 11 of 15 RCTs showed improvement compared to control groups. Importantly, 18 of 21 studies demonstrated cartilage protection and/or repair on imaging. [9]

Mechanism Understanding: Research has established that MSCs work through both direct differentiation and paracrine mechanisms, with their immunomodulatory "fitness" correlating with treatment efficacy. [9]The trophic (supportive) and immunomodulatory effects are now understood to be as important as—if not more important than—direct tissue replacement. [5]

Safety Profile: A comprehensive review by Lalu et al. (2012) examining 36 clinical trials found no significant safety concerns with MSC therapy, with adverse events comparable to control groups. [10]This safety profile has been confirmed in subsequent larger studies and meta-analyses.

Evidence for Respiratory Conditions

COPD and Chronic Lung Disease: A systematic review and meta-analysis by Calzetta et al. (2022) analyzed data from 371 COPD patients across 11 studies. Active treatments demonstrated: [11]

  • A strong tendency toward improved lung function (FEV1 improvement of +71 mL)
  • Significantly increased 6-minute walk distance (+52 meters vs. baseline/control, p < 0.05)
  • Favorable safety profile with no significant adverse events

A 2024 comprehensive review confirmed that MSCs show promise for COPD due to their anti-inflammatory, reparative, and immunomodulatory properties, with the potential to rescue impaired lung function and architecture. [12]

The Role of Exosomes

Emerging Evidence: MSC-derived exosomes are showing remarkable therapeutic potential. A 2024 review in the International Journal of Molecular Sciences demonstrated that MSC-exosomes can: [7]

  • Alleviate cartilage degradation
  • Reduce synovial inflammation
  • Protect subchondral bone
  • Promote regeneration without the risks of cell transplantation

Laboratory studies have shown that UC-MSC-derived exosomes promote cartilage regeneration in animal models of osteoarthritis by downregulating inflammatory markers (MMP-13, ADAMTS-5) and upregulating collagen II production. [13]

What the Numbers Show

Ongoing Research

As of 2026, ClinicalTrials.gov lists 196 actively recruiting clinical trials involving mesenchymal stem cells, investigating applications from orthopedics to autoimmune conditions, respiratory diseases, diabetes, and neurological disorders. [15]The field continues to advance rapidly, with new insights into optimal dosing, cell sources, and combination therapies.

Deep Dive: The Biology of Stem Cells

This section provides additional scientific detail for readers seeking comprehensive understanding.

Molecular Mechanisms of Self-Renewal

Stem cells maintain their undifferentiated state through a network of transcription factors, primarily: [3]

  • Oct4 (POU5F1): Master regulator of pluripotency
  • Sox2: Works with Oct4 to maintain stem cell identity
  • Nanog: Prevents differentiation signals

These factors form a self-reinforcing circuit, activating genes that maintain "stemness" while repressing differentiation genes. External signals from the stem cell niche—the microenvironment where stem cells reside—regulate this balance through pathways including Wnt, Notch, and Hedgehog.

Telomerase and the Hayflick Limit

Most human cells can only divide 50–70 times before reaching the Hayflick limit—the point where telomeres (protective caps on chromosomes) become too short for further division. Stem cells express telomerase, an enzyme that rebuilds telomeres, allowing extended proliferation. However, this capacity decreases with age, contributing to reduced healing potential.

Epigenetic Regulation

Cell fate is controlled by epigenetic modifications—chemical changes to DNA and histone proteins that don't alter the genetic code but determine which genes are active:

  • DNA methylation: Adding methyl groups to DNA silences genes
  • Histone acetylation: Modifying histone proteins opens DNA for transcription

During differentiation, epigenetic patterns progressively restrict cell potential. This is why reprogramming adult cells to iPSCs requires "erasing" these marks—a process discovered by Yamanaka. [3]

Immunomodulatory Properties of MSCs

MSCs don't just regenerate tissue—they actively modulate immune responses. [8]They:

  • Suppress T-cell proliferation
  • Inhibit dendritic cell maturation
  • Promote regulatory T-cell formation
  • Reduce pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)

This makes MSCs particularly valuable for conditions involving inflammation, such as osteoarthritis (where inflammatory cytokines contribute to cartilage degradation), COPD (characterized by chronic airway inflammation), and autoimmune conditions. [9,][12]

The Paracrine Hypothesis

Modern understanding has shifted from viewing MSCs primarily as "replacement cells" to recognizing them as "medicinal signaling cells"—a term coined by Arnold Caplan, who originally named MSCs. [5]The therapeutic benefit comes largely from:

  1. Secretome: The full collection of factors secreted by MSCs
  2. Exosomes: Nano-sized vesicles carrying proteins, mRNA, and microRNA
  3. Mitochondrial transfer: Direct transfer of healthy mitochondria to damaged cells

This explains why relatively few transplanted MSCs (many of which don't survive long-term) can produce lasting therapeutic effects—they activate the body's own repair mechanisms. [5,][7]

Why Different Cell Sources Matter

Research has compared MSCs from different tissue sources: [2]

The Umbilical Cord Advantage

For many patients, particularly those over 50, umbilical cord-derived MSCs (UC-MSCs) offer compelling advantages:

  1. Youth and Potency: UC-MSCs come from newborn tissue, exhibiting high proliferative capacity and robust differentiation potential—unlike aged cells from older donors. [24]
  2. Immediate Availability: No invasive harvest procedure required. Cells can be administered on the same day as evaluation, enabling efficient treatment protocols.
  3. Anti-Aging Properties: Research demonstrates that UC-MSC-derived extracellular vesicles contain "abundant anti-aging signals" that can rejuvenate older cells. [24]
  4. Lower Immunogenicity: UC-MSCs express low levels of HLA class II antigens, reducing rejection risk even though they're from a donor. [16]
  5. Consistent Quality: Professionally processed umbilical cord tissue from screened, healthy births provides standardized, high-quality cell populations.

A 2024 network meta-analysis found that all three major MSC sources (bone marrow, adipose, umbilical cord) showed efficacy for knee osteoarthritis, with some evidence suggesting umbilical cord-derived MSCs may have advantages for certain applications, particularly in older patients whose own cells have declined in function. [16]

For patients seeking regenerative therapy: The choice between autologous (your own cells) and allogeneic (donor cells) often comes down to age and treatment goals. Younger patients with acute injuries may benefit from their own cells, while older patients or those seeking anti-aging benefits often do better with young, potent umbilical cord-derived cells.

A Brief History: From Discovery to Treatment

Understanding where we've come from helps appreciate where we're going.

Conditions Where Stem Cell Therapy Shows Promise

Based on current research and clinical evidence, MSC therapy has shown particular promise for:

Musculoskeletal Conditions

  • Knee osteoarthritis: Most extensively studied; strong evidence for pain reduction and cartilage preservation [9,][14]
  • Hip osteoarthritis: Growing evidence; similar mechanisms to knee OA
  • Shoulder injuries: Rotator cuff tears, labral injuries
  • Sports injuries: Tendon, ligament, and meniscus damage
  • Degenerative spine conditions: Disc degeneration, facet joint arthritis

Respiratory Conditions

  • COPD/Emphysema: Evidence for improved exercise capacity and potential lung function improvement [11,][12]
  • Pulmonary fibrosis: Emerging research on fibrosis reduction
  • Chronic bronchitis: Anti-inflammatory and repair mechanisms

Other Conditions Under Investigation

  • Autoimmune disorders: Leveraging immunomodulatory properties
  • Diabetes: Supporting pancreatic function and reducing complications
  • Cardiovascular disease: Post-heart attack regeneration
  • Neurological conditions: Stroke recovery, traumatic brain injury

Important: The strength of evidence varies by condition. Knee osteoarthritis has the most robust clinical data, while other applications remain in earlier stages of research.

Stem Cells for Healthy Individuals: Optimization & Longevity

A growing body of research suggests that stem cell therapy isn't just for treating disease—it may help healthy individuals maintain vitality and slow age-related decline.

The Science of Aging and Stem Cells

As we age, our endogenous (built-in) stem cell populations decline in both number and function. [21]This contributes to:

  • Slower healing from injuries
  • Loss of muscle mass and strength
  • Decreased immune function
  • Accumulated chronic inflammation ("inflammaging")
  • Reduced tissue repair and regeneration

Aging frailty—characterized by weakness, reduced endurance, and vulnerability to stressors—is increasingly understood as a stem cell depletion syndrome. [22]The question researchers have asked: can replenishing stem cells reverse or slow these changes?

Clinical Evidence: The CRATUS Trial

The landmark CRATUS trial (2017) was a Phase II randomized, double-blind, placebo-controlled study that tested allogeneic (donor-derived) MSCs in patients with aging frailty. [21]

Key Findings:

  • 100 million MSCs produced optimal results
  • Physical performance improved significantly: 6-minute walk test, short physical performance exam, and lung function (FEV1) all improved (p = 0.01)
  • Inflammatory markers decreased: Serum TNF-α levels dropped (p = 0.03)
  • Immune function improved: B-cell intracellular TNF-α improved dramatically (p < 0.0001)
  • Quality of life improved: Female sexual quality of life scores improved (p = 0.03)
  • Safe: No therapy-related serious adverse events

The researchers concluded that MSC therapy produced "remarkable improvements in physical performance measures and inflammatory biomarkers, both of which characterize the frailty syndrome." [21]

Umbilical Cord MSCs for Aging: The 2024 Evidence

A 2024 Phase I/II randomized controlled trial specifically tested umbilical cord-derived MSCs for aging frailty, with compelling results: [23]

Outcomes at 6 months:

  • Quality of life: Significant improvement in physical component scores from the first treatment visit, sustained throughout follow-up (p = 0.042)
  • Physical performance: Timed Up and Go test showed continual enhancement over 6 months (p < 0.05)
  • Walking ability: 4-meter walking test improved by 2.05 seconds
  • Grip strength: Significantly better performance, particularly at 6 months (p = 0.002)
  • Reduced inflammation: TNF-α and IL-17 levels declined compared to placebo (p = 0.034 and 0.033)

The study concluded that "intravenous transplantation of HUC-MSCs is a safe and effective therapeutic approach on aging frailty." [23]

Why Healthier Patients May Respond Better

Here's an important insight that many people miss: the healthier you are, the better stem cell therapy tends to work.

Why? Because stem cells don't work in isolation. They:

  • Interact with your existing immune system
  • Rely on your body's signaling pathways
  • Require adequate circulation to reach target tissues
  • Work synergistically with your endogenous repair mechanisms

In a healthier body:

  • Lower baseline inflammation means MSCs can focus on regeneration rather than fighting chronic inflammation
  • Better circulation delivers MSCs and their therapeutic factors more effectively
  • Stronger immune system responds more robustly to MSC signaling
  • Healthier tissue microenvironment supports engraftment and differentiation

This is why leading regenerative medicine protocols often include preparatory treatments to optimize the body before MSC administration—reducing inflammation, improving circulation, and supporting cellular energy production.

The Anti-Aging Potential of Umbilical Cord-Derived Products

Research published in Science Translational Medicine (2021) demonstrated that extracellular vesicles from umbilical cord MSCs contain "abundant anti-aging signals" and can: [24]

  • Rejuvenate aging adult MSCs: Restoring their self-renewal capacity
  • Increase telomere length: The protective caps on chromosomes that shorten with age
  • Reduce age-related organ degeneration: Including bone and kidney deterioration in animal models
  • Transfer key regenerative factors: Including PCNA (proliferating cell nuclear antigen)

The researchers concluded that "UC-EVs are of high translational value in anti-aging intervention." [24]

Who Might Benefit?

Stem cell therapy for optimization and longevity may be appropriate for:

  • Healthy adults 40+ seeking to maintain vitality and slow age-related decline
  • High-performing individuals (executives, athletes, active retirees) wanting to preserve peak function
  • Those with early signs of frailty: Decreased energy, slower recovery, mild cognitive changes
  • Proactive health optimizers: Biohackers and wellness-focused individuals

Important: While the research is promising, stem cell therapy for healthy aging is still an emerging field. The strongest evidence comes from frailty studies, with ongoing research exploring optimization in healthy populations.

Combination Therapies: The Multi-Modal Approach

Modern regenerative medicine increasingly uses combination protocols that leverage multiple therapeutic mechanisms: [5,][7]

The Preparation-Enhancement Principle

Leading regenerative clinics understand that preparing the body before stem cell administration can significantly improve outcomes. A typical advanced protocol might include:

Day 1: Preparation Phase

  • Exosome therapy: MSC-derived exosomes begin the regenerative signaling cascade
  • NAD+ (Nicotinamide adenine dinucleotide): A critical coenzyme that supports cellular energy, DNA repair, and reduces chronic inflammation [25]
  • Comprehensive blood panel: Establishes baseline health markers for personalized treatment

Day 2+: MSC Therapy

  • Up to 100 million umbilical cord MSCs (50M per session): Administered after the body has been optimally prepared
  • The reduced inflammation from Day 1 creates a more receptive environment
  • MSCs can focus on regeneration rather than fighting chronic inflammation

Why This Sequence Matters: Research shows that the tissue microenvironment significantly affects MSC function. [5]By reducing baseline inflammation and supporting cellular energy production first, the subsequent MSC therapy can achieve better results.

Common Combination Approaches

Advanced Immunotherapy Options

For patients seeking the most comprehensive regenerative protocols—particularly those addressing immune function, cancer surveillance, or chronic infections—cellular immunotherapy represents the cutting edge:

NKT Cells (Natural Killer T Cells) and NK Cells

  • Powerful immune cells that target abnormal and infected cells
  • Can be cultured from the patient's own blood (autologous)
  • Require 2–3 weeks of laboratory expansion
  • Used for immune optimization, cancer support, and chronic viral infections

Important: Because NKT/NK cell therapy requires culturing the patient's own blood cells, it is typically offered as:

  • A component of extended treatment stays (3+ weeks)
  • A second-visit option after initial MSC therapy
  • A premium personalized protocol for specific indications

This represents the most advanced tier of regenerative medicine—personalized cellular therapy tailored to each individual's immune profile.

Why Combinations May Work Better

  1. Multiple mechanisms: Address different aspects of damage simultaneously
  2. Synergistic effects: Therapies may enhance each other's effectiveness
  3. Sustained benefit: Different components work at different time scales
  4. Personalization: Can be tailored to individual patient needs

Research suggests that combining MSCs with adjunctive therapies like PRP may enhance outcomes compared to either therapy alone. [18]

What This Means for You

If you're dealing with joint pain, a respiratory condition, or a degenerative disease that hasn't responded to conventional treatment, here's what you should understand:

The Opportunity

Stem cell therapy offers a fundamentally different approach than traditional treatments:

  • Pain medications mask symptoms but don't address underlying damage
  • Steroid injections reduce inflammation temporarily but may accelerate cartilage loss long-term
  • Surgery replaces damaged tissue with artificial materials or removes tissue entirely
  • Inhalers and bronchodilators manage respiratory symptoms but don't repair lung tissue

Stem cell therapy aims to regenerate—to help your body rebuild what's been lost.

The Reality Check

Stem cells are not magic. They work best when:

  • The condition is appropriate (not all problems respond equally)
  • The patient is properly selected (some people are better candidates)
  • The treatment protocol is optimized for the individual
  • Expectations are realistic
  • Lifestyle factors support healing (nutrition, activity, avoiding re-injury)

Results vary. Some patients experience dramatic improvement; others see modest benefits. The science is promising and rapidly advancing, but it's not a guarantee. [9]

Questions to Consider

Before exploring stem cell treatment, ask yourself:

  1. What is my diagnosis, and has stem cell therapy shown efficacy for this condition?
  2. What have I already tried, and why hasn't it worked?
  3. Am I a good candidate based on age, health status, and severity?
  4. What are realistic expectations for my specific situation?
  5. Am I ready to commit to the full treatment process, including any recommended follow-up?

Frequently Asked Questions

Are stem cells safe?

Clinical studies involving thousands of patients have demonstrated that MSC therapy has a favorable safety profile. [10]The most common side effects are minor—temporary pain or swelling at injection sites. Serious adverse events are rare. A 2012 systematic review of 36 clinical trials found no significant safety concerns compared to control groups, and this has been reaffirmed in subsequent larger studies. However, like any medical procedure, there are risks that should be discussed with your provider.

Where do the stem cells come from?

For most regenerative treatments, stem cells come from one of three sources:

  • Your own body (autologous)—from bone marrow or fat tissue
  • Donated umbilical cord tissue (allogeneic)—from healthy, screened births with full maternal consent
  • Donated bone marrow or adipose tissue (allogeneic)—from screened donors

The source depends on the treatment protocol and your specific situation. Umbilical cord-derived MSCs are gaining popularity due to their young, potent characteristics and the lack of invasive harvesting for the patient. [16]

How is this different from embryonic stem cell therapy?

Most clinical stem cell treatments use adult stem cells (particularly MSCs) or umbilical cord-derived cells—not embryonic stem cells. These don't involve embryos and don't carry the same ethical concerns. Umbilical cord tissue is collected after healthy births with informed consent and would otherwise be discarded.

What about exosomes? Are they different from stem cells?

Exosomes are tiny messenger particles (30–150 nanometers) released by stem cells. They carry much of the therapeutic "cargo"—proteins, growth factors, and genetic material—that helps repair tissue. [7]Some clinics now offer exosome therapy as a standalone treatment or in combination with MSC therapy. The advantage is that exosomes avoid some risks associated with cell transplantation while still providing regenerative benefits.

Why isn't my doctor offering this?

Stem cell therapy for conditions like osteoarthritis exists in a complex regulatory landscape. In many countries, these treatments aren't yet approved as standard of care, even though they're widely used internationally and have substantial clinical evidence. [9]This doesn't mean they don't work—it means:

  • Regulatory approval processes take years and require expensive trials
  • Insurance companies don't cover most regenerative treatments
  • Medical schools focus on established treatments, not emerging therapies
  • Many physicians simply aren't trained in regenerative medicine

Patients seeking these treatments often travel to specialized clinics or countries with more progressive regulatory frameworks for regenerative medicine.

How long until I see results?

Most patients begin noticing improvement within 4–12 weeks, with continued progress over 6–12 months as tissue regeneration occurs. Unlike pain medication that works immediately, stem cell therapy initiates a healing process that takes time. The timeline varies by:

  • Condition being treated
  • Severity of damage
  • Patient age and overall health
  • Treatment protocol used

Can anyone get stem cell therapy?

Not everyone is a good candidate. Factors that influence candidacy include:

Potentially favorable factors:

  • Earlier-stage disease (before severe degeneration)
  • Good overall health
  • Non-smoker or willing to quit
  • Realistic expectations
  • Lower baseline inflammation

Factors that may reduce candidacy:

  • Very advanced disease (e.g., Grade 4 bone-on-bone with significant deformity)
  • Active infections
  • Certain cancers or blood disorders
  • Uncontrolled diabetes or autoimmune conditions
  • Inability to follow post-treatment protocols

A proper evaluation by a qualified specialist is essential to determine if you're a candidate.

I'm healthy. Why would I consider stem cell therapy?

This is one of the most important developments in regenerative medicine. Research now shows that MSC therapy can benefit healthy individuals seeking to: [21,][23]

  • Maintain vitality as you age: Combat the natural decline in stem cell function that begins in your 40s
  • Reduce chronic low-grade inflammation: "Inflammaging" accelerates nearly all age-related conditions
  • Support immune function: MSCs can help rebalance and optimize immune responses
  • Enhance recovery capacity: Return faster from workouts, travel, and stress

The CRATUS trial demonstrated that even in participants classified as "frail," 100 million MSCs produced significant improvements in physical performance, immune markers, and quality of life—with no serious adverse events. [21]

Key insight: The healthier you are when you start, the better your results tend to be. MSCs work synergistically with your body's existing systems. In a well-functioning body with lower inflammation and better circulation, stem cell therapy can help you maintain that advantage longer.

Think of it like maintaining a high-performance vehicle: you don't wait until the engine fails to service it. Proactive regenerative support may help preserve function rather than just restore it after damage occurs.

Take the Next Step

Understanding stem cells is the foundation for making informed decisions about your health. If you're considering regenerative treatment options:

→ Take Our 2-Minute Health Assessment

Find out if you might be a candidate for regenerative therapy

→ Download: The Surgery-Free Guide to Joint Recovery

Learn about all your options for treating joint pain without going under the knife

→ Download: Living Beyond Your Oxygen Tank

A guide for COPD patients exploring regenerative options

→ Schedule a Discovery Call

Speak with a specialist about your specific situation

Explore the evidence by condition: Knee Osteoarthritis | Hip Arthritis | Shoulder & Rotator Cuff | Elbow Tendinopathy | Wrist & Hand | Back Pain | COPD | Stroke Recovery | Parkinson's Disease | Peripheral Neuropathy | Erectile Dysfunction | Hair Loss | Skin Rejuvenation

This content is for educational purposes only and does not constitute medical advice. Stem cell treatments are not FDA-approved for most conditions discussed. Individual results vary significantly. The regulatory status of these therapies differs by country. Always consult with a qualified healthcare provider before making treatment decisions.

References

  1. Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D., Moorman, M.A., Simonetti, D.W., Craig, S. and Marshak, D.R. (1999). Multilineage potential of adult human mesenchymal stem cells. , 284 , pp. 143–147 doi:10.1126/science.284.5411.143 Tier 1
  2. Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., Deans, R., Keating, A., Prockop, D. and Horwitz, E. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 8 , pp. 315–317 doi:10.1080/14653240600855905 Tier 1
  3. Takahashi, K. and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. , 126 , pp. 663–676 doi:10.1016/j.cell.2006.07.024 Tier 1
  4. Giorgino, R., Albano, D., Fusco, S., Peretti, G.M., Mangiavini, L. and Messina, C. (2023). Knee osteoarthritis: Epidemiology, pathogenesis, and mesenchymal stem cells: What else is new? An update. , 24 doi:10.3390/ijms24076405 Tier 1
  5. Caplan, A.I. and Dennis, J.E. (2006). Mesenchymal stem cells as trophic mediators. , 98 , pp. 1076–1084 doi:10.1002/jcb.20886 Tier 1
  6. Théry, C., Witwer, K.W., Aikawa, E. et al. (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles. , 7 doi:10.1080/20013078.2018.1535750 Tier 1
  7. Vadhan, A., Gupta, T. and Hsu, W.L. (2024). Mesenchymal stem cell-derived exosomes as a treatment option for osteoarthritis. , 25 doi:10.3390/ijms25179149 Tier 1
  8. Molnar, V., Pavelić, E., Vrdoljak, K., Čemerin, M., Klarić, E., Matišić, V., Bjelica, R., Brlek, P., Kovačić, I., Tremolada, C. and Primorac, D. (2022). Mesenchymal stem cell mechanisms of action and clinical effects in osteoarthritis: A narrative review. , 13 doi:10.3390/genes13060949 Tier 1
  9. Copp, G., Robb, K.P. and Viswanathan, S. (2023). Culture-expanded mesenchymal stromal cell therapy: Does it work in knee osteoarthritis? A pathway to clinical success. , 20 , pp. 626–650 doi:10.1038/s41423-023-01020-1 Tier 1
  10. Lalu, M.M., McIntyre, L., Pugliese, C., Fergusson, D., Winston, B.W., Marshall, J.C., Granton, J. and Stewart, D.J. (2012). Safety of cell therapy with mesenchymal stromal cells (SafeCell): A systematic review and meta-analysis of clinical trials. , 7 doi:10.1371/journal.pone.0047559 Tier 1
  11. Calzetta, L., Aiello, M., Frizzelli, A., Camardelli, F., Cazzola, M., Rogliani, P. and Chetta, A. (2022). Stem cell-based regenerative therapy and derived products in COPD: A systematic review and meta-analysis. , 11 doi:10.3390/cells11111797 Tier 1
  12. Lai, S. and Guo, Z. (2024). Stem cell therapies for chronic obstructive pulmonary disease: Mesenchymal stem cells as a promising treatment option. , 15 , pp. 03940-9 doi:10.1186/s13287-024-03940-9 Tier 1
  13. Yang, H., Zhou, Y., Ying, B., Dong, X., Qian, Q. and Gao, S. (2024). Effects of human umbilical cord mesenchymal stem cell-derived exosomes in the rat osteoarthritis models. , 13 , pp. 803–811 doi:10.1093/stcltm/szae031 Tier 1
  14. Yubo, M., Yanyan, L., Li, L., Tao, S., Bo, L. and Lin, C. (2017). Clinical efficacy and safety of mesenchymal stem cell transplantation for osteoarthritis treatment: A meta-analysis. , 12 doi:10.1371/journal.pone.0175449 Tier 1
  15. ClinicalTrials.gov (2026). Search results: Mesenchymal stem cell - recruiting studies. [Link] Tier 2
  16. Chen, X., Zheng, J., Yin, L., Li, Y. and Liu, H. (2024). Transplantation of three mesenchymal stem cells for knee osteoarthritis, which cell and type are more beneficial? A systematic review and network meta-analysis. , 19 , pp. 04846-1 doi:10.1186/s13018-024-04846-1 Tier 1
  17. Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J., Marshall, V.S. and Jones, J.M. (1998). Embryonic stem cell lines derived from human blastocysts. , 282 , pp. 1145–1147 doi:10.1126/science.282.5391.1145 Tier 1
  18. Lamo-Espinosa, J.M., Blanco, J.F., Sánchez, M., Moreno, V., Granero-Moltó, F., Sánchez-Guijo, F., Crespo-Cullel, Í., Mora, G., San Vicente, D.D., Pompei-Fernández, O., Aquerreta, J.D., Núñez-Córdoba, J.M., Vitoria Sola, M., Valentí-Azcárate, A., Andreu, E.J., Del Consuelo Del Cañizo, M., Valentí-Nin, J.R. and Prósper, F. (2020). Phase II multicenter randomized controlled clinical trial on the efficacy of intra-articular injection of autologous bone marrow mesenchymal stem cells with platelet rich plasma for the treatment of knee osteoarthritis. , 18 , pp. 02530-6 doi:10.1186/s12967-020-02530-6 Tier 1
  19. International Society for Stem Cell Research (2021). Guidelines for Stem Cell Research and Clinical Translation. [Link] Tier 2
  20. Melo, M.M., Cruz, F.F. and Rocco, P.R.M. (2023). Mesenchymal stromal cell therapy for chronic lung diseases: Experimental and clinical evidence. , 17 , pp. 223–235 doi:10.1080/17476348.2023.2196015 Tier 1
  21. Tompkins, B.A., DiFede, D.L., Khan, A., Landin, A.M., Schulman, I.H., Pujol, M.V., Heldman, A.W., Miki, R., Goldschmidt-Clermont, P.J., Goldstein, B.J., Mushtaq, M., Levis-Dusseau, S., Byrnes, J.J., Lowery, M., Natsumeda, M., Delber, C., Balber, R., Oliva, A.A. and Hare, J.M. (2017). Allogeneic mesenchymal stem cells ameliorate aging frailty: A phase II randomized, double-blind, placebo-controlled clinical trial. , 72 , pp. 1513–1522 doi:10.1093/gerona/glx137 Tier 1
  22. Zhu, Y., Ge, J., Huang, C., Liu, H. and Jiang, H. (2021). Application of mesenchymal stem cell therapy for aging frailty: From mechanisms to therapeutics. , 11 , pp. 5675–5685 doi:10.7150/thno.46436 Tier 1
  23. Zhu, Y., Huang, C., Zheng, L., Li, Q., Ge, J., Geng, S., Zhai, M., Chen, X., Yuan, H., Li, Y., Jia, W., Sun, K., Li, Y., Ye, T., Zhao, Z., Liu, H., Liu, Z. and Jiang, H. (2024). Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: A phase I/II randomized, double-blind, placebo-controlled study. , 15 , pp. 03707-2 doi:10.1186/s13287-024-03707-2 Tier 1
  24. Lei, Q., Gao, F., Liu, T., Ren, W., Chen, L., Cao, Y., Chen, W., Guo, S., Zhang, Q., Chen, W., Wang, H., Chen, Z., Li, Q., Hu, Y. and Guo, A. (2021). Extracellular vesicles deposit PCNA to rejuvenate aged bone marrow-derived mesenchymal stem cells and slow age-related degeneration. , 13 doi:10.1126/scitranslmed.aaz8697 Tier 1
  25. Rajman, L., Chwalek, K. and Bhupinder, S.P. (2018). Therapeutic potential of NAD-boosting molecules: The in vivo evidence. , 27 , pp. 529–547 doi:10.1016/j.cmet.2018.02.011 Tier 1

Ready to Learn More?

Discover if regenerative medicine is right for you.

Take Free Assessment